S&P 500   4,960.48 (-1.01%)
DOW   37,914.86 (+0.37%)
QQQ   414.27 (-2.16%)
AAPL   164.93 (-1.26%)
MSFT   399.46 (-1.19%)
META   480.21 (-4.30%)
GOOGL   153.68 (-1.49%)
AMZN   173.91 (-2.96%)
TSLA   147.04 (-1.93%)
NVDA   771.66 (-8.86%)
AMD   145.95 (-5.89%)
NIO   3.81 (-4.75%)
BABA   69.04 (+0.23%)
T   16.51 (+1.10%)
F   12.08 (+0.17%)
MU   106.25 (-5.07%)
GE   148.23 (-3.08%)
CGC   7.96 (+1.66%)
DIS   112.17 (-0.23%)
AMC   3.18 (+8.90%)
PFE   25.93 (+2.13%)
PYPL   61.76 (-0.55%)
XOM   119.81 (+1.09%)
S&P 500   4,960.48 (-1.01%)
DOW   37,914.86 (+0.37%)
QQQ   414.27 (-2.16%)
AAPL   164.93 (-1.26%)
MSFT   399.46 (-1.19%)
META   480.21 (-4.30%)
GOOGL   153.68 (-1.49%)
AMZN   173.91 (-2.96%)
TSLA   147.04 (-1.93%)
NVDA   771.66 (-8.86%)
AMD   145.95 (-5.89%)
NIO   3.81 (-4.75%)
BABA   69.04 (+0.23%)
T   16.51 (+1.10%)
F   12.08 (+0.17%)
MU   106.25 (-5.07%)
GE   148.23 (-3.08%)
CGC   7.96 (+1.66%)
DIS   112.17 (-0.23%)
AMC   3.18 (+8.90%)
PFE   25.93 (+2.13%)
PYPL   61.76 (-0.55%)
XOM   119.81 (+1.09%)
S&P 500   4,960.48 (-1.01%)
DOW   37,914.86 (+0.37%)
QQQ   414.27 (-2.16%)
AAPL   164.93 (-1.26%)
MSFT   399.46 (-1.19%)
META   480.21 (-4.30%)
GOOGL   153.68 (-1.49%)
AMZN   173.91 (-2.96%)
TSLA   147.04 (-1.93%)
NVDA   771.66 (-8.86%)
AMD   145.95 (-5.89%)
NIO   3.81 (-4.75%)
BABA   69.04 (+0.23%)
T   16.51 (+1.10%)
F   12.08 (+0.17%)
MU   106.25 (-5.07%)
GE   148.23 (-3.08%)
CGC   7.96 (+1.66%)
DIS   112.17 (-0.23%)
AMC   3.18 (+8.90%)
PFE   25.93 (+2.13%)
PYPL   61.76 (-0.55%)
XOM   119.81 (+1.09%)
S&P 500   4,960.48 (-1.01%)
DOW   37,914.86 (+0.37%)
QQQ   414.27 (-2.16%)
AAPL   164.93 (-1.26%)
MSFT   399.46 (-1.19%)
META   480.21 (-4.30%)
GOOGL   153.68 (-1.49%)
AMZN   173.91 (-2.96%)
TSLA   147.04 (-1.93%)
NVDA   771.66 (-8.86%)
AMD   145.95 (-5.89%)
NIO   3.81 (-4.75%)
BABA   69.04 (+0.23%)
T   16.51 (+1.10%)
F   12.08 (+0.17%)
MU   106.25 (-5.07%)
GE   148.23 (-3.08%)
CGC   7.96 (+1.66%)
DIS   112.17 (-0.23%)
AMC   3.18 (+8.90%)
PFE   25.93 (+2.13%)
PYPL   61.76 (-0.55%)
XOM   119.81 (+1.09%)
LON:PRM

Proteome Sciences (PRM) Share Price, News & Analysis

GBX 3.30
+0.25 (+8.20%)
(As of 04/19/2024 ET)
Today's Range
2.91
3.60
50-Day Range
2.82
4.50
52-Week Range
2.65
8.79
Volume
247,243 shs
Average Volume
157,436 shs
Market Capitalization
£9.74 million
P/E Ratio
418.00
Dividend Yield
6.17%
Price Target
N/A
PRM stock logo

About Proteome Sciences Stock (LON:PRM)

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. It offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the important factor. The company also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers, as well as bioinformatics tools. It primarily serves pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.

PRM Stock Price History

PRM Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Proteome Sciences PLC (PRM.AQ)
Proteome Sciences opens lab in San Diego
Proteome Sciences opens lab in San Diego’s biotech hub
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Proteome Sciences
See More Headlines
Receive PRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Proteome Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/10/2020
Today
4/19/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
29
Year Founded
N/A

Profitability

Net Income
£1.32 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£7.75 million
Cash Flow
GBX 0.89 per share

Miscellaneous

Free Float
N/A
Market Cap
£9.74 million
Optionable
Not Optionable
Beta
-0.03
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Dr. Mariola Sohngen (Age 63)
    CEO & Executive Director
    Comp: $310k
  • Mr. Abdelghani Omari (Age 48)
    CFO & Director
    Comp: $209k
  • Dr. Ian H. Pike (Age 60)
    Chief Scientific Officer & Executive Director
    Comp: $233k
  • Mr. Richard Paul Dennis (Age 66)
    Chief Commercial Officer & Executive Director
    Comp: $235k
  • Mr. Glenn Barney
    Vice President of Sales & Marketing
  • Victoria Joanna Birse
    Company Secretary

PRM Stock Analysis - Frequently Asked Questions

How have PRM shares performed in 2024?

Proteome Sciences' stock was trading at GBX 4.53 on January 1st, 2024. Since then, PRM stock has decreased by 27.2% and is now trading at GBX 3.30.
View the best growth stocks for 2024 here
.

How were Proteome Sciences' earnings last quarter?

Proteome Sciences plc (LON:PRM) announced its quarterly earnings data on Monday, August, 10th. The company reported ($0.17) EPS for the quarter.

What other stocks do shareholders of Proteome Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Proteome Sciences investors own include ValiRx (VAL), boohoo group (BOO), Mondi (MNDI), Petrofac (PFC), Lloyds Banking Group (LLOY), Falanx Group (FLX), Quanterix (QTRX), Centrica (CNA), CyanConnode (CYAN) and Eckoh (ECK).

How do I buy shares of Proteome Sciences?

Shares of PRM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:PRM) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners